Insights into the Maturation Heterogeneity of Tumor-Associated Tertiary Lymphoid Structures in Cancer Immunotherapy
Wen Xu,Jianfeng Yang,Shiqi Ye,Wangrui Liu,Jiahe Lu,Aihetaimujiang Anwaier,Hailiang Zhang,Dingwei Ye
DOI: https://doi.org/10.2217/imt-2023-0196
2024-01-01
Immunotherapy
Abstract:ImmunotherapyAhead of Print EditorialInsights into the maturation heterogeneity of tumor-associated tertiary lymphoid structures in cancer immunotherapyWenhao Xu‡, Jianfeng Yang‡, Shiqi Ye‡, Wangrui Liu‡, Jiahe Lu, Aihetaimujiang Anwaier, Hailiang Zhang & Dingwei YeWenhao Xu‡ https://orcid.org/0000-0002-0660-9162Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, P.R. ChinaShanghai Genitourinary Cancer Institute, Shanghai, 200032, P.R. China‡Contribute equally to this workSearch for more papers by this author, Jianfeng Yang‡Department of Surgery, Pudong branch of Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 1000 Shangnan Road, Shanghai, 200126, China‡Contribute equally to this workSearch for more papers by this author, Shiqi Ye‡Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, P.R. ChinaShanghai Genitourinary Cancer Institute, Shanghai, 200032, P.R. China‡Contribute equally to this workSearch for more papers by this author, Wangrui Liu‡Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, P.R. China‡Contribute equally to this workSearch for more papers by this author, Jiahe LuDepartment of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, P.R. ChinaShanghai Genitourinary Cancer Institute, Shanghai, 200032, P.R. ChinaSchool of Cellular & Molecular Medicine, University of Bristol, Bristol, BS8 1TD, UKSearch for more papers by this author, Aihetaimujiang AnwaierDepartment of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, P.R. ChinaShanghai Genitourinary Cancer Institute, Shanghai, 200032, P.R. ChinaSearch for more papers by this author, Hailiang Zhang *Author for correspondence: E-mail Address: zhanghl918@alu.fudan.edu.cnhttps://orcid.org/0000-0001-8408-7446Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, P.R. ChinaShanghai Genitourinary Cancer Institute, Shanghai, 200032, P.R. ChinaSearch for more papers by this author & Dingwei Ye **Author for correspondence: E-mail Address: dingwei_ye@fudan.edu.cnhttps://orcid.org/0000-0003-4974-3780Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, P.R. ChinaShanghai Genitourinary Cancer Institute, Shanghai, 200032, P.R. ChinaSearch for more papers by this authorPublished Online:19 Dec 2023https://doi.org/10.2217/imt-2023-0196AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: cancer immunotherapyimmune-infiltrating lymphocytestertiary lymphoid structurestumor microenvironmentPapers of special note have been highlighted as: • of interest; •• of considerable interestReferences1. Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19(6), 307–325 (2019). • This study underscores the growing significance of tertiary lymphoid structures (TLS) in tumor immunity due to its distinctive location and robust immune function. The integrated analysis strategy incorporating spatial and single-cell transcriptomics profoundly elucidates the immune mechanisms in tumors and their relevance to clinical immunotherapy by examining the unique structure, cellular composition and gene expression patterns within TLS. This approach is poised to substantially influence future research in the scientific field.Crossref, Medline, CAS, Google Scholar2. Domblides C, Rochefort J, Riffard C et al. Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation. Front. Immunol. 12, 698604 (2021).Crossref, Medline, CAS, Google Scholar3. Kinker GS, Vitiello GAF, Diniz AB et al. Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas. Gut 72(10), 1927–1941 (2023).Crossref, Medline, CAS, Google Scholar4. Munoz-Erazo L, Rhodes JL, Marion VC, Kemp RA. Tertiary lymphoid structures in cancer – considerations for patient prognosis. Cell Mol. Immunol. 17(6), 570–575 (2020).Crossref, Medline, CAS, Google Scholar5. Vanhersecke L, Brunet M, Guégan JP et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat. Cancer 2(8), 794–802 (2021). • The findings from this study highlight the predictive capability of TLS in determining the efficacy of immune checkpoint inhibitors, independent of PD-L1 expression, presenting robust evidence for the potential development of TLS-based predictive biomarkers. Furthermore, within mature TLS, the collaboration between B cells and dendritic cells is observed to enhance the training of CD8+ T cells by facilitating the transfer of tumor antibodies, underscoring the functional intricacies within the tumor microenvironment.Crossref, Medline, CAS, Google Scholar6. Posch F, Silina K, Leibl S et al. Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. Oncoimmunology 7(2), e1378844 (2018).Crossref, Medline, Google Scholar7. Fridman WH, Meylan M, Petitprez F, Sun CM, Italiano A, Sautès-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat. Rev. Clin. Oncol. 19(7), 441–457 (2022).Crossref, Medline, CAS, Google Scholar8. Meylan M, Petitprez F, Becht E et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55(3), 527–541; e5 (2022).Crossref, Medline, CAS, Google Scholar9. Dieu-Nosjean MC, Giraldo NA, Kaplon H, Germain C, Fridman WH, Sautès-Fridman C. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol. Rev. 271(1), 260–275 (2016).Crossref, Medline, CAS, Google Scholar10. Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science 375(6576), eabf9419 (2022). •• The paper delves into an in-depth exploration of the current understanding of TLS in cancer, encompassing discussions on the underlying drivers of TLS formation, their pivotal function in shaping tumor immune responses, and their potential as a therapeutic target in human cancers.Crossref, Medline, CAS, Google Scholar11. Siliņa K, Soltermann A, Attar FM et al. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. Cancer Res. 78(5), 1308–1320 (2018). • A key milestone of this study lies in its pioneering identification of TLS maturity using multiple fluorescent markers to predict the prognosis and treatment response in patients with solid tumors. This work underscores the significance of TLS maturity heterogeneity as an essential factor in evaluating its clinical value, potentially revolutionizing prognostic assessments in the oncological landscape.Crossref, Medline, CAS, Google Scholar12. Allen E, Jabouille A, Rivera LB et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci. Transl. Med. 9(385), 1–28 (2017).Crossref, Google Scholar13. Sato Y, Silina K, van den Broek M, Hirahara K, Yanagita M. The roles of tertiary lymphoid structures in chronic diseases. Nat. Rev. Nephrol. 19(8), 525–537 (2023).Crossref, Medline, Google Scholar14. Ukita M, Hamanishi J, Yoshitomi H et al. CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. JCI Insight 7(12), 1–15 (2022).Crossref, Google Scholar15. Dai S, Zeng H, Liu Z et al. Intratumoral CXCL13(+)CD8(+)T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma. J. Immunother. Cancer 9(2), 1–10; e001823 (2021).Crossref, Google Scholar16. Truxova I, Kasikova L, Hensler M et al. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. J. Immunother. Cancer 6(1), 139 (2018).Crossref, Medline, Google Scholar17. Asrir A, Tardiveau C, Coudert J et al. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell 40(3), 318–334; e9 (2022).Crossref, Medline, CAS, Google Scholar18. Rodriguez AB, Peske JD, Woods AN et al. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Rep. 36(3), 109422 (2021).Crossref, Medline, CAS, Google Scholar19. Xu W, Liu W, Yang J, Lu J, Zhang H, Ye D. Stimuli-responsive nanodelivery systems for amplifying immunogenic cell death in cancer immunotherapy. Immunol. Rev. doi: 10.1111/imr.13237 (2023) (Epub ahead of print).Crossref, Google Scholar20. Galluzzi L, Humeau J, Buqué A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17(12), 725–741 (2020).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetails Ahead of Print STAY CONNECTED Metrics Downloaded 0 times History Received 16 August 2023 Accepted 17 November 2023 Published online 19 December 2023 Information© 2023 Future Medicine LtdKeywordscancer immunotherapyimmune-infiltrating lymphocytestertiary lymphoid structurestumor microenvironmentAuthor contributionsConceptualization: W Xu, W Liu, A Anwaier, J Lu and S Ye. Funding acquisition: W Xu, H Zhang and D Ye. Supervision: J Yang, H Zhang and D Ye. Original draft: W Xu, W Liu, A Anwaier and S Ye. Editing: H Zhang and D Ye.Financial disclosureThis work was supported by grants from the Shanghai Anticancer Association EYAS PROJECT (No. SACA-CY21A06 and SACA-CY21B01), and Shanghai Municipal Health Bureau (No.2020CXJQ03). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.Competing interests disclosureThe authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.Writing disclosureNo writing assistance was utilized in the production of this manuscript.PDF download
What problem does this paper attempt to address?
-
Clinical Significance of Tertiary Lymphoid Structure Maturity in Colorectal Cancer Patients
Jiangjiang Zheng,Jingjing Yu,Jingjing Xie,Dong Chen,Hong Deng
DOI: https://doi.org/10.3724/zdxbyxb-2024-0320
2024-01-01
Abstract:OBJECTIVES:To explore the clinical significance of the maturation of tertiary lymphoid structures (TLS) in colorectal cancer patients. METHODS:A total of 230 surgical removed colorectal cancer specimens with detailed follow-up data were collected from Yinzhou Second Hospital. There were 128 cases of mature TLS and 108 cases of immature TLS according to immunohistochemical results. The patient age, gender, maximum tumor diameter, tumor location, differentiation degree, depth of invasion, lymph node metastasis, vascular tumor thrombus, liver metastasis, distant non-liver metastasis, mismatch repair status, expression of Ki-67, P53 and programmed cell death ligand 1 (PD-L1) were analyzed. The Kaplan-Meier method (Breslow test) was used to analyze the survival of patients, and multivariate Cox regression model was applied to analyze the prognostic factors. RESULTS:Compared to the immature TLS group, the mature TLS group showed a significantly lower rate of vascular tumor thrombus, lymph node metastasis, and liver metastasis. Additionally, the positive expression rate of Ki-67 was markedly reduced, while the rate of deficient mismatch repair and the positive expression rate of PD-L1 were significantly increased (all P<0.05). The overall survival rate of the mature TLS group was superior to that of the immature TLS group (Breslow=4.553, P<0.05). Cox regression analysis indicated that lymph node metastasis was an independent risk factor for the prognosis of colorectal cancer patients (P<0.01), while TLS maturation was a protective factor (P<0.05). CONCLUSIONS:The formation of TLS may play a significant role in inhibiting lymph node metastasis, liver metastasis, and vascular tumor thrombus in colorectal cancer, and patients with mature TLS have a favorable clinical prognosis, which can provide a reference for the immunotherapy and prognostic assessment of colorectal cancer patients.
-
Mature tertiary lymphoid structures: important contributors to anti-tumor immune efficacy
Xinyu Bao,Xuwen Lin,Mei Xie,Jie Yao,Jialin Song,Xidong Ma,Xin Zhang,Yinguang Zhang,Yiming Liu,Wenya Han,Yiran Liang,Hongling Hu,Li Xu,Xinying Xue
DOI: https://doi.org/10.3389/fimmu.2024.1413067
2024-07-04
Abstract:Tertiary lymphoid structures (TLS) represent the ectopic aggregations of immune cells arising during chronic inflammation or tumor progression. In cancer, TLS are often associated with beneficial clinical outcomes in patients undergoing immunotherapy, underscoring their prognostic and predictive significance. Mature TLS, characterized by germinal centers and areas of T-cell and B-cell aggregation, are considered primary locations for activating and maintaining both humoral and cellular anti-tumor immune effects. Despite their recognized importance, the mechanisms driving the formation of mature TLS in cancer and their influence on the immune response within tumors remain insufficiently understood. Therefore, this review aims to comprehensively explore the structural composition, development mechanisms, maturity impact factors, immunological function, and innovative therapeutic strategies of mature TLS within the tumor microenvironment. The research summarized herein offers novel insights and considerations for therapeutic approaches to promote TLS generation and maturation in patients with cancer, representing a promising avenue for future cancer therapies.
-
Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers
Marie-Caroline Dieu-Nosjean,Nicolas A Giraldo,Hélène Kaplon,Claire Germain,Wolf Herman Fridman,Catherine Sautès-Fridman
DOI: https://doi.org/10.1111/imr.12405
Abstract:The characterization of the microenvironment of human tumors led to the description of tertiary lymphoid structures (TLS) characterized by mature dendritic cells in a T-cell zone adjacent to B-cell follicle including a germinal center. TLS represent sites of lymphoid neogenesis that develop in most solid cancers. Analysis of the current literature shows that the TLS presence is associated with a favorable clinical outcome for cancer patients, regardless of the approach used to quantify TLS and the stage of the disease. Using several approaches that combine immunohistochemistry, gene expression assays, and flow cytometry on large series of lung tumors, our work demonstrated that TLS are important sites for the initiation and/or maintenance of the local and systemic T- and B-cell responses against tumors. Surrounded by high endothelial venules, they represent a privileged area for the recruitment of lymphocytes into tumors and generation of central-memory T and B cells that circulate and limit cancer progression. TLS can be considered as a novel biomarker to stratify the overall survival risk of untreated cancer patients and as a marker of efficient immunotherapies. The induction and manipulation of cancer-associated TLS using drug agonists and/or biotherapies should open new avenues to treat cancer patients.
-
Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation
Charlotte Domblides,Juliette Rochefort,Clémence Riffard,Marylou Panouillot,Géraldine Lescaille,Jean-Luc Teillaud,Véronique Mateo,Marie-Caroline Dieu-Nosjean
DOI: https://doi.org/10.3389/fimmu.2021.698604
IF: 7.3
2021-06-30
Frontiers in Immunology
Abstract:The tumor microenvironment is a complex ecosystem almost unique to each patient. Most of available therapies target tumor cells according to their molecular characteristics, angiogenesis or immune cells involved in tumor immune-surveillance. Unfortunately, only a limited number of patients benefit in the long-term of these treatments that are often associated with relapses, in spite of the remarkable progress obtained with the advent of immune checkpoint inhibitors (ICP). The presence of “hot” tumors is a determining parameter for selecting therapies targeting the patient immunity, even though some of them still do not respond to treatment. In human studies, an in-depth analysis of the organization and interactions of tumor-infiltrating immune cells has revealed the presence of an ectopic lymphoid organization termed tertiary lymphoid structures (TLS) in a large number of tumors. Their marked similarity to secondary lymphoid organs has suggested that TLS are an “anti-tumor school” and an “antibody factory” to fight malignant cells. They are effectively associated with long-term survival in most solid tumors, and their presence has been recently shown to predict response to ICP inhibitors. This review discusses the relationship between TLS and the molecular characteristics of tumors and the presence of oncogenic viruses, as well as their role when targeted therapies are used. Also, we present some aspects of TLS biology in non-tumor inflammatory diseases and discuss the putative common characteristics that they share with tumor-associated TLS. A detailed overview of the different pre-clinical models available to investigate TLS function and neogenesis is also presented. Finally, new approaches aimed at a better understanding of the role and function of TLS such as the use of spheroids and organoids and of artificial intelligence algorithms, are also discussed. In conclusion, increasing our knowledge on TLS will undoubtedly improve prognostic prediction and treatment selection in cancer patients with key consequences for the next generation immunotherapy.
immunology
-
Insights into tertiary lymphoid structures in the solid tumor microenvironment: anti-tumor mechanism, functional regulation, and immunotherapeutic strategies
Hua Zhao,Hao Wang,Qiuru Zhou,Xiubao Ren
DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0029
2021-09-24
Cancer Biology and Medicine
Abstract:Tertiary lymphoid structures (TLSs) are ectopic immune cell aggregations that develop in peripheral tissues in response to a wide range of chronic inflammatory conditions, including infection, autoimmune disease, and cancer. In the tumor microenvironment (TME), the structures of TLSs, including B-cell- and T-cell-enriched areas indicate that the TLSs might be the local site during the initiation and maintenance of humoral and cellular immune responses against cancers. Numerous studies have evaluated the expression of TLSs in different cancer patients and their association with prognoses of cancer patients. It was shown that welldeveloped TLSs characterized by mature B cells synthesized tumor specific antibodies, which were considered as specific markers for a good prognosis. However, there are still some immunosuppressive factors existing in the TLSs that may affect anti-tumor responses. These factors include dysfunctional B cells, regulatory T cells, and T follicular regulatory cells. The complexity and heterogeneity of the TLS composition may affect the function and activity of TLSs; it is therefore essential to fully understand the function and influencing factors in TLSs. It has been reported that checkpoint inhibitors and vaccines are currently being developed to reprogram the TME by establishing mature TLSs to improve cancer immunotherapies. In this review, we focused on recent advances in TLSs in human solid tumors, including structural characteristics and classes, antitumor mechanisms, immunosuppressive factors, and TLSbased therapeutic approaches.
oncology,medicine, research & experimental
-
Tertiary Lymphoid Structure and B‑cell‑related Pathways: A Potential Target in Tumor Immunotherapy (Review)
Meng Qin,Ying Jin,Lingya Pan
DOI: https://doi.org/10.3892/ol.2021.13097
2021-01-01
Oncology Letters
Abstract:The tertiary lymphoid structure (TLS), also referred to as the ectopic lymphoid structure, has recently become a focus of attention. The TLS consists of T-cell and B-cell-rich regions, as well as plasma cells, follicular helper T cells, follicular dendritic cells (FDCs), germinal centers (GCs) and high endothelial venules. TLSs can be divided into different subtypes and mature stages according to the density of FDCs and GCs. The TLS serves as an effective site in which an antitumor inflammatory response is generated through infiltrating immune cells. B-cell-related pathways, known as the CXC chemokine ligand 13/CXC chemokine receptor type 5 axis and the CC chemokine ligand (CCL)19/CCL21/CC-chemokine receptor 7 axis, play a key role in the generation and formation of TLSs. The aim of the present review was to systematically summarize updated research progress on the formation, subtypes, evaluation and B-cell-related pathways of TLSs. Furthermore, researchers have previously reported that TLSs are present in several types of solid cancers and that they are associated with survival outcomes. Therefore, studies on TLS in breast, lung, colorectal and ovarian cancers and melanoma were summarized and compared. The TLS and B-cell-related pathways require further investigation as important immune signals and promising new immunotherapy targets in the era of T-cell therapy revolution.
-
Tertiary lymphoid structures in the era of cancer immunotherapy
Catherine Sautès-Fridman,Florent Petitprez,Julien Calderaro,Wolf Herman Fridman
DOI: https://doi.org/10.1038/s41568-019-0144-6
IF: 78.5
2019-05-15
Nature Reviews Cancer
Abstract:Tertiary lymphoid structures (TLSs) are ectopic lymphoid organs that develop in non-lymphoid tissues at sites of chronic inflammation including tumours. Key common characteristics between secondary lymphoid organogenesis and TLS neogenesis have been identified. TLSs exist under different maturation states in tumours, culminating in germinal centre formation. The mechanisms that underlie the role of TLSs in the adaptive antitumour immune response are being deciphered. The description of the correlation between TLS presence and clinical benefit in patients with cancer, suggesting that TLSs could be a prognostic and predictive factor, has drawn strong interest into investigating the role of TLSs in tumours. A current major challenge is to exploit TLSs to promote lymphocyte infiltration, activation by tumour antigens and differentiation to increase the antitumour immune response. Several approaches are being developed using chemokines, cytokines, antibodies, antigen-presenting cells or synthetic scaffolds to induce TLS formation. Strategies aiming to induce TLS neogenesis in immune-low tumours and in immune-high tumours, in this case, in combination with therapeutic agents dampening the inflammatory environment and/or with immune checkpoint inhibitors, represent promising avenues for cancer treatment.
oncology
-
Tertiary lymphoid structures in cancer: maturation and induction
Yulu Chen,Yuhao Wu,Guorong Yan,Guolong Zhang
DOI: https://doi.org/10.3389/fimmu.2024.1369626
IF: 7.3
2024-04-17
Frontiers in Immunology
Abstract:Tertiary lymphoid structure (TLS) is an ectopic lymphocyte aggregate formed in peripheral non-lymphoid tissues, including inflamed or cancerous tissue. Tumor-associated TLS serves as a prominent center of antigen presentation and adaptive immune activation within the periphery, which has exhibited positive prognostic value in various cancers. In recent years, the concept of maturity regarding TLS has been proposed and mature TLS, characterized by well-developed germinal centers, exhibits a more potent tumor-suppressive capacity with stronger significance. Meanwhile, more and more evidence showed that TLS can be induced by therapeutic interventions during cancer treatments. Thus, the evaluation of TLS maturity and the therapeutic interventions that induce its formation are critical issues in current TLS research. In this review, we aim to provide a comprehensive summary of the existing classifications for TLS maturity and therapeutic strategies capable of inducing its formation in tumors.
immunology
-
Tertiary lymphoid structures and their therapeutic implications in cancer
Xun Chen,Pan Wu,Ziqi Liu,Tiansheng Li,Jie Wu,Zhaoyang Zeng,Wenjia Guo,Wei Xiong
DOI: https://doi.org/10.1007/s13402-024-00975-1
2024-08-12
Abstract:Tertiary lymphoid structures (TLSs) are ectopic lymphoid aggregates formed by the structured accumulation of immune cells such as B cells and T cells in non-lymphoid tissues induced by infection, inflammation, and tumors. They play a crucial role in the immune response, particularly in association with tumor development, where they primarily exert anti-tumor immune functions during tumorigenesis. Current research suggests that TLSs inhibit tumor growth by facilitating immune cell infiltration and are correlated with favorable prognosis in various solid tumors, serving as an indicator of immunotherapy effectiveness to some extent. Therefore, TLSs hold great promise as a valuable biomarker. Most importantly, immunotherapies aimed to prompting TLSs formation are anticipated to be potent adjuncts to current cancer treatment. This review focuses on the formation process of TLSs and their potential applications in cancer therapy.
-
Tertiary lymphoid structures in anticancer immunity
Jean-Luc Teillaud,Ana Houel,Marylou Panouillot,Clémence Riffard,Marie-Caroline Dieu-Nosjean
DOI: https://doi.org/10.1038/s41568-024-00728-0
Abstract:Tertiary lymphoid structures (TLS) are transient ectopic lymphoid aggregates where adaptive antitumour cellular and humoral responses can be elaborated. Initially described in non-small cell lung cancer as functional immune lymphoid structures associated with better clinical outcome, TLS have also been found in many other carcinomas, as well as melanomas and sarcomas, and associated with improved response to immunotherapy. The manipulation of TLS as a therapeutic strategy is now coming of age owing to the likely role of TLS in the improved survival of patients with cancer receiving immune checkpoint inhibitor treatment. TLS have also garnered considerable interest as a predictive biomarker of the response to antitumour therapies, including immune checkpoint blockade and, possibly, chemotherapy. However, several important questions still remain regarding the definition of TLS in terms of both their cellular composition and functions. Here, we summarize the current views on the composition of TLS at different stages of their development. We also discuss the role of B cells and T cells associated with TLS and their dialogue in mounting antibody and cellular antitumour responses, as well as some of the various mechanisms that negatively regulate antitumour activity of TLS. The prognostic value of TLS to the clinical outcome of patients with cancer and the relationship between TLS and the response to therapy are then addressed. Finally, we present some preclinical evidence that favours the idea that manipulating the formation and function of TLS could lead to a potent next-generation cancer immunotherapy.
-
Tertiary Lymphoid Structures: An Anti-tumor School for Adaptive Immune Cells and an Antibody Factory to Fight Cancer?
Jean-Luc Teillaud,Marie-Caroline Dieu-Nosjean
DOI: https://doi.org/10.3389/fimmu.2017.00830
IF: 7.3
2017-07-21
Frontiers in Immunology
Abstract:Tertiary lymphoid structures (TLS) present in human solid tumors are essential for the shaping of a favorable immune micro-environment to control tumor development in most cases. They represent a formidable school for T-cell priming, B cell activation, and differentiation into plasma cells and an exquisitely located factory for antibody production. The manipulation of TLS neogenesis and maintenance represents, therefore, an exciting task to set up efficient anti-cancer vaccine strategies leading to long-lasting anti-tumor adaptive responses. To achieve this goal, a number of important issues are still pending. How TLS-T and -B cells and antibodies locally produced are related to the improved survival of cancer patients with high density of TLS is still unclear. In addition, the mechanisms by which tumors escape the immune surveillance exerted by TLS are still poorly understood and the role of immune suppressive cytokines, regulatory T cells, and/or antibodies in this process remains to be explored. The identification of the key parameters that distinguish TLS with anti- or possible pro-tumor activity is also essential to make the therapeutic targeting of TLS a success. Finally, how TLS-based therapeutic approaches can be associated with targeted therapies or immunointerventions, such as the use of ICP blockers to improve anti-tumor responses, is an open question. We will discuss these different issues in the present review.
immunology
-
Tertiary lymphoid structures are critical for cancer prognosis and therapeutic response
Qianqian Zhang,Suhui Wu
DOI: https://doi.org/10.3389/fimmu.2022.1063711
IF: 7.3
2023-01-11
Frontiers in Immunology
Abstract:Tertiary lymphoid structures (TLSs) are ectopic lymphocyte aggregates that form at sites of chronic inflammation, including cancers, in non-lymphoid tissues. Although the formation of TLSs is similar to that of secondary lymphoid organs, the pathogenic factors leading to TLS formation in cancerous tissues and the mechanisms underlying the role of these structures in the intra-tumoral adaptive antitumor immune response are not fully understood. The presence of TLSs may impact patient prognosis and treatment outcomes. This review examines the current understanding of TLSs in cancers, including their composition and formation as well as their potential to predict prognosis and therapeutic efficacy. We also summarize strategies to induce TLS formation for cancer treatment.
immunology
-
Tertiary lymphoid structures as unique constructions associated with the organization, education, and function of tumor-infiltrating immunocytes
Jing Chen,Jian Chen,Lie Wang
DOI: https://doi.org/10.1631/jzus.B2200174
2022-10-18
Abstract:Tertiary lymphoid structures (TLSs) are formations at sites with persistent inflammatory stimulation, including tumors. These ectopic lymphoid organs mainly consist of chemo-attracting B cells, T cells, and supporting dendritic cells (DCs). Mature TLSs exhibit functional organization for the optimal development and collaboration of adaptive immune response, delivering an augmented effect on the tumor microenvironment (TME). The description of the positive correlation between TLSs and tumor prognosis is reliable only under a certain condition involving the localization and maturation of TLSs. Emerging evidence suggests that underlying mechanisms of the anti-tumor effect of TLSs pave the way for novel immunotherapies. Several approaches have been developed to take advantage of intratumoral TLSs, either by combining it with therapeutic agents or by inducing the neogenesis of TLSs.
-
Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies
Marta Trüb,Alfred Zippelius
DOI: https://doi.org/10.3389/fimmu.2021.674565
IF: 7.3
2021-05-12
Frontiers in Immunology
Abstract:Tertiary lymphoid structures (TLS) are ectopic lymphoid formations which are formed under long-lasting inflammatory conditions, including tumours. TLS are composed predominantly of B cells, T cells and dendritic cells, and display various levels of organisation, from locally concentrated aggregates of immune cells, through clearly defined B cell follicles to mature follicles containing germinal centres. Their presence has been strongly associated with improved survival and clinical outcome upon cancer immunotherapies for patients with solid tumours, indicating potential for TLS to be used as a prognostic and predictive factor. Although signals involved in TLS generation and main cellular components of TLS have been extensively characterised, the exact mechanism by which TLS contribute to the anti-tumour response remain unclear. Here, we summarise the most recent development in our understanding of their role in cancer and in particular in the response to cancer immunotherapy. Deciphering the relationship between B cells and T cells found in TLS is a highly exciting field of investigation, with the potential to lead to novel, B-cell focused immunotherapies.
immunology
-
Tertiary lymphoid structures and cytokines interconnections: The implication in cancer immunotherapy
Hao Li,Jia-Yi Ding,Meng-Jie Zhang,Hai-Jun Yu,Zhi-Jun Sun
DOI: https://doi.org/10.1016/j.canlet.2023.216293
IF: 9.756
2023-06-30
Cancer Letters
Abstract:Tertiary lymphoid structures (TLSs) are organized aggregates of lymphocytes and antigen-presenting cells that develop in non-lymphoid tissues during chronic inflammation, resembling the structure and features of secondary lymphoid organs. Numerous studies have shown that TLSs may be an important source of antitumor immunity within solid tumors, facilitating T cell and B cell differentiation and the subsequent production of antitumor antibodies, which are beneficial for cancer prognosis and responses to immunotherapy. The formation of TLS relies on the cytokine signaling network between heterogeneous cell populations, such as stromal cells, lymphocytes and cancer cells. The coordinated action of various cytokines drives the complex process of TLS development. In this review, we will comprehensively describe the mechanisms by which various cytokines regulate TLS formation and function, and the recent advancements and therapeutic potential of exploiting these mechanisms to induce TLS as an emerging immunotherapeutic approach or to enhance existing immunotherapy.
oncology
-
Tertiary lymphoid structures in cancer: immune mechanisms and clinical implications
Siyu Wang,Hua Wang,Chenbei Li,Binfeng Liu,Shasha He,Chao Tu
DOI: https://doi.org/10.1002/mco2.489
2024-03-11
Abstract:Cancer is a major cause of death globally, and traditional treatments often have limited efficacy and adverse effects. Immunotherapy has shown promise in various malignancies but is less effective in tumors with low immunogenicity or immunosuppressive microenvironment, especially sarcomas. Tertiary lymphoid structures (TLSs) have been associated with a favorable response to immunotherapy and improved survival in cancer patients. However, the immunological mechanisms and clinical significance of TLS in malignant tumors are not fully understood. In this review, we elucidate the composition, neogenesis, and immune characteristics of TLS in tumors, as well as the inflammatory response in cancer development. An in-depth discussion of the unique immune characteristics of TLSs in lung cancer, breast cancer, melanoma, and soft tissue sarcomas will be presented. Additionally, the therapeutic implications of TLS, including its role as a marker of therapeutic response and prognosis, and strategies to promote TLS formation and maturation will be explored. Overall, we aim to provide a comprehensive understanding of the role of TLS in the tumor immune microenvironment and suggest potential interventions for cancer treatment.
-
Tertiary Lymphoid Structures: A Potential Biomarker for Anti-Cancer Therapy
Ji'an Zou,Yingzhe Zhang,Yue Zeng,Yurong Peng,Junqi Liu,Chaoyue Xiao,Fang Wu
DOI: https://doi.org/10.3390/cancers14235968
2022-12-02
Abstract:A tertiary lymphoid structure (TLS) is a special component in the immune microenvironment that is mainly composed of tumor-infiltrating lymphocytes (TILs), including T cells, B cells, DC cells, and high endothelial venules (HEVs). For cancer patients, evaluation of the immune microenvironment has a predictive effect on tumor biological behavior, treatment methods, and prognosis. As a result, TLSs have begun to attract the attention of researchers as a new potential biomarker. However, the composition and mechanisms of TLSs are still unclear, and clinical detection methods are still being explored. Although some meaningful results have been obtained in clinical trials, there is still a long way to go before such methods can be applied in clinical practice. However, we believe that with the continuous progress of basic research and clinical trials, TLS detection and related treatment can benefit more and more patients. In this review, we generalize the definition and composition of TLSs, summarize clinical trials involving TLSs according to treatment methods, and describe possible methods of inducing TLS formation.
-
404MO Tertiary Lymphoid Structures Localization and Maturation Heterogeneities Correlate with Divergent Microenvironment Features and Immune Responses of Clear Cell Renal Cell Carcinoma
W. Xu,H. Zhang,D. Ye,W. Liu
DOI: https://doi.org/10.1016/j.annonc.2023.10.499
IF: 51.769
2023-01-01
Annals of Oncology
Abstract:Tertiary lymphoid structures (TLS) are organized aggregates of immune cells that form postnatally in non-lymphoid tissues and arise under pathological conditions. The prognostic and predictive value of TLS in the tumor microenvironment (TME) has strengthened interest as potential mediators of antitumor immunity. Immunohistochemistry and multispectral fluorescent were used to evaluate the TLS heterogeneity along with TME cell-infiltrating characterizations. We comprehensively assessed the prognostic and immunological implications of the TLS heterogeneity in 625 patients with ccRCC from multiply cohorts. Associations between TLS heterogeneity and immunologic activities were assessed by the quantification of immune cells infiltration. TLS typically comprises B-cell follicles with germinal centers and are surrounded by T-cell zones and dendritic cells. TLS infiltrates were identified in 34.2% of the ccRCC samples, with intratumoral, peritumoral, and both in 37.8%, 74.1%, and 11.9% of the TLS-positive cases, respectively. A higher proportion of early TLS was found in peritumoral TLS (P=0.016), while intratumoral TLS mainly comprised secondary follicle-like (P=0.004). Kaplan-Meier analyses indicated that the presence of mature TLS (namely SFL-TLS, with CD23+ germinal center) markedly correlated with both better survival. Notably, presence of TLS, especially intratumoral TLS and SFL-TLS significantly correlated with better survival and objective reflection rate for ccRCC patients receiving anti-PD-1/PD-L1 immunotherapies. Interestingly, in ccRCC samples with the presence of peritumoral TLS enriched with primary follicle-like TLS, the proportion of tumor-associated macrophages and Treg infiltration in the peritumoral regions increased prominently, showing a typical suppressive TME characterizations. In conclusion, this study for the first time revealed the implications of TLS localization and maturation heterogeneity on the immunological status and responses of ccRCC, allowing the identification of immunophenotypes and the improvement of immunotherapeutic effectiveness for ccRCC.
-
Mechanisms of tertiary lymphoid structure formation: cooperation between inflammation and antigenicity
Shrijan Khanal,Andreas Wieland,Andrew J. Gunderson
DOI: https://doi.org/10.3389/fimmu.2023.1267654
IF: 7.3
2023-09-21
Frontiers in Immunology
Abstract:To mount an effective anti-tumor immune response capable of controlling or eliminating disease, sufficient numbers of lymphocytes must be recruited to malignant tissue and allowed to sustain their effector functions. Indeed, higher infiltration of T and B cells in tumor tissue, often referred to as “hot tumors”, is prognostic for patient survival and predictive of response to immunotherapy in almost all cancer types. The organization of tertiary lymphoid structures (TLS) in solid tumors is a unique example of a hot tumor whereby T and B lymphocytes aggregate with antigen presenting cells and high endothelial venules reflecting the cellular organization observed in lymphoid tissue. Many groups have reported that the presence of preexisting TLS in tumors is associated with a superior adaptive immune response, response to immunotherapy, and improved survivorship over those without TLS. Accordingly, there is significant interest into understanding the mechanisms of how and why TLS organize so that they can be elicited therapeutically in patients with few or no TLS. Unfortunately, the most commonly used mouse models of cancer do not spontaneously form TLS, thus significantly restricting our understanding of TLS biology. This brief review will summarize our current state of knowledge of TLS neogenesis and address the current gaps in the field.
immunology
-
Tertiary lymphoid structures accompanied by fibrillary matrix morphology impact anti-tumor immunity in basal cell carcinomas
Candice Byers,Melissa Gill,Nicholas R. Kurtansky,Christi Alessi-Fox,Maggie Harman,Miguel Cordova,Salvador Gonzalez,Pascale Guitera,Veronica Rotemberg,Ashfaq Marghoob,Chih-Shan Jason Chen,Jennifer Dy,Kivanc Kose,Milind Rajadhyaksha,Aditi Sahu
DOI: https://doi.org/10.3389/fmed.2022.981074
IF: 3.9
2022-10-27
Frontiers in Medicine
Abstract:Tertiary lymphoid structures (TLS) are specialized lymphoid formations that serve as local repertoire of T- and B-cells at sites of chronic inflammation, autoimmunity, and cancer. While presence of TLS has been associated with improved response to immune checkpoint blockade therapies and overall outcomes in several cancers, its prognostic value in basal cell carcinoma (BCC) has not been investigated. Herein, we determined the prognostic impact of TLS by relating its prevalence and maturation with outcome measures of anti-tumor immunity, namely tumor infiltrating lymphocytes (TILs) and tumor killing. In 30 distinct BCCs, we show the presence of TLS was significantly enriched in tumors harboring a nodular component and more mature primary TLS was associated with TIL counts. Moreover, assessment of the fibrillary matrix surrounding tumors showed discrete morphologies significantly associated with higher TIL counts, critically accounting for heterogeneity in TIL count distribution within TLS maturation stages. Specifically, increased length of fibers and lacunarity of the matrix with concomitant reduction in density and alignment of fibers were present surrounding tumors displaying high TIL counts. Given the interest in inducing TLS formation as a therapeutic intervention as well as its documented prognostic value, elucidating potential impediments to the ability of TLS in driving anti-tumor immunity within the tumor microenvironment warrants further investigation. These results begin to address and highlight the need to integrate stromal features which may present a hindrance to TLS formation and/or effective function as a mediator of immunotherapy response.
medicine, general & internal